Advanced Proteome Therapeutics Corporation
Other OTCTotal Valuation
Advanced Proteome Therapeutics Corporation carries a market capitalization of 149,630.00, placing it among publicly traded companies globally. Its enterprise value stands at 1.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 149,630.00 |
| Enterprise Value | 1.60M |
Share Statistics
Advanced Proteome Therapeutics Corporation currently has 41.13M shares outstanding.
| Shares Outstanding | 41.13M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Advanced Proteome Therapeutics Corporation trades at a trailing price-to-earnings ratio of 3.43.
| PE Ratio | 3.43 |
| PS Ratio | N/A |
| PB Ratio | -74.03 |
| P/TBV Ratio | -74.03 |
| P/FCF Ratio | -1.23 |
| P/OCF Ratio | -1.23 |
Financial Position
Advanced Proteome Therapeutics Corporation maintains a current ratio of 0.73, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -141.65, indicating conservative leverage, while an interest coverage ratio of -26.29 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.73 |
| Quick Ratio | 0.73 |
| Debt / Equity | -141.65 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | -26.29 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -444.91 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Income Statement
EBITDA reached -944,513.00, while operating income came in at -950,595.00.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -950,595.00 |
| Pretax Income | -2.21M |
| Net Income | -2.04M |
| EBITDA | -944,513.00 |
| EBIT | -950,595.00 |
| Earnings Per Share (EPS) | -0.05 |
Balance Sheet
Advanced Proteome Therapeutics Corporation holds 38,705.00 in cash and equivalents against 30,790.00 in total debt, resulting in a net debt position of -7,915.00. Total book value stands at -21,737.00, with working capital of -22,871.00 providing operational flexibility.
| Cash & Cash Equivalents | 38,705.00 |
| Total Debt | 30,790.00 |
| Net Debt | -7,915.00 |
| Equity (Book Value) | -21,737.00 |
| Book Value Per Share | 0.00 |
| Working Capital | -22,871.00 |
Cash Flow
Advanced Proteome Therapeutics Corporation produced -1.31M in operating cash flow over the past twelve months. After subtracting -1,351.00 in capital expenditures, free cash flow totaled -1.31M - equivalent to -0.03 per share.
| Operating Cash Flow | -1.31M |
| Capital Expenditures | -1,351.00 |
| Free Cash Flow | -1.31M |
| FCF Per Share | -0.03 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -6.98 |
| FCF Yield | -81.17 |
Stock Splits
Advanced Proteome Therapeutics Corporation's most recent stock split took place on May 8, 2019 with a 10:1 split ratio.
| Last Split Date | 5/8/2019 |
| Split Ratio | 10:1 |
Scores
Advanced Proteome Therapeutics Corporation posts an Altman Z-Score of -491.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -491.37 |